

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451

Date: November 18, 2025

To,
The Manager-Listing
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Mumbai – 400051

Respected Sir/Ma'am,

Sub: Update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Receipt of Letter of Acceptance.

Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received a Letter of Acceptance on November 17, 2025 amounting to **approximately Rs. 27,63,89,634/-** i.e. (Rupees Twenty-Seven Crore Sixty-Three Lakh Eighty-Nine Thousand Six Hundred Thirty-Four Only) exclusive of GST from **Rajasthan Medical Services Corporation Limited** for supply of various pharmaceuticals products.

This order presents a remarkable opportunity for our company to further demonstrate its manufacturing capabilities and to strengthen our relationship with our customers, thereby contributing positively to its business growth prospects.

Further Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed as Annexure A.

You are requested to kindly note the same.

Thanking you,

Yours faithfully,
For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad

Encl: A/a-

Registered Office:

Plot No. PF21 & PF-22/A, Charal Industrial Estate,
Sanand GIDC-II, Sanand,
Ahmedabad- 382110, Gujarat.

CIN.: L24230GJ2015PLC085451**Annexure A**

Details with respect to said order as required under regulation 30 of listing regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 are attached herewith:

Sr. No.	Particulars	Details
1.	Name of the entity awarding the order(s)/contract(s);	Rajasthan Medical Services Corporation Limited
2.	Whether order(s) / contract(s) have been awarded by domestic/ international entity ;	Domestic
3.	Nature of Contract, significant terms and conditions of order awarded, broad commercial consideration or size of the order;	The Company has received a Letter of Acceptance amounting to approximately Rs. 27,63,89,634/- i.e. (Rupees Twenty-Seven Crore Sixty-Three Lakh Eighty- Nine Thousand Six Hundred Thirty-Four Only) exclusive of GST from Rajasthan Medical Services Corporation Limited for supply of pharmaceuticals products i.e. Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5% under the Tender of Drug & Medicines to be executed in accordance with the terms and conditions outlined in the tender documents.
4.	Time period by which the order(s)/contract(s) is to be executed;	The supply under the said contract is to be executed up to March 31, 2027.
5.	Whether the promoter/ promoter group / group companies have any interest in the entity that awarded the order(s)/contract(s)? If yes, nature of interest and details thereof;	No
6.	Whether the order(s)/contract(s) would fall within related party transactions? If yes, whether the same is done at "arm's length".	No

For, Sotac Pharmaceuticals Limited

Sharadkumar Dashrathbhai Patel
Chairman and Managing Director
DIN: 07252252

Place: Ahmedabad